PM
ORIC icon

Prosight Management’s Oric Pharmaceuticals ORIC Stock Holding History

Prosight Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-200,000
Closed -$1.84M – 47
2023
Q4 		$1.84M Buy
+200,000
New +$1.45M 0.74% 27

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management's ORIC Position: Q1 2024 in Review

Prosight Management sold out of Oric Pharmaceuticals (ORIC) in Q1 2024, closing a stake of 1,578,263 shares — an estimated $14.5M sold.

Prosight Management first reported a position in ORIC in Q3 2022 and held it in 6 quarters. The position peaked at $21.4M in Q2 2023. 112 funds tracked by Wall St. Rank hold ORIC as of Q1 2024.

  • Prosight Management reported no remaining Oric Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Prosight Management sold 1,578,263 Oric Pharmaceuticals shares in Q1 2024, an estimated $14.5M.
  • Prosight Management first reported a position in Oric Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • Prosight Management's Oric Pharmaceuticals position peaked at $21.4M in Q2 2023.
  • 112 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2024.

Based on Prosight Management's 13F filing for Q1 2024, filed 15 May 2024.